 |
市場調查報告書
商品編碼
1424384
小兒科抗癲癇藥物市場：按藥物類型、給藥途徑、分銷管道和地區分類Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計到 2030 年，全球小兒科抗癲癇藥物市場規模將從 2023 年的 12.024 億美元增至 20.347 億美元，預測期內年複合成長率（CAGR）為 7.8%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2022年 | 2023/2024年市場規模 | 12.024 億美元 |
| 過去的資料 | 2018-2021 | 預測期 | 2023-2030 |
| 預測期間 2023/2024 至 2030/2031 年複合年成長率： | 7.80% | 2030/2031價值預測 | 20.347 億美元 |
圖 1. 2023 年按地區分類的小兒科抗癲癇藥物全球市場佔有率(%)
癲癇是一種常見的神經系統疾病，影響全世界各個年齡層的人。然而，這種情況在兒童中更為常見，因為近 70% 的癲癇患者是在成年之前被診斷出來的。抗癲癇藥物在控制癲癇發作和改善癲癇兒童患者的生活品質方面發揮著重要作用。這些藥物透過控制大腦中異常神經細胞的放電和同步來預防癲癇發作。近年來，廣泛的研究和開發導致了新一代小兒科抗癲癇藥物的開發和核准，這些藥物更有效且副作用更少。這對兒童癲癇患者的藥物醫囑遵從性和治療結果有正面影響。兒童癲癇的原因包括創傷、出生併發症和遺傳性疾病。由腦膜炎等腦部感染疾病引起的癲癇稱為症狀性癲癇，與遺傳有關的疾病稱為特發性癲癇。
市場動態
全球小兒科抗癲癇藥物市場受到兒童癲癇盛行率不斷上升的推動。根據世界衛生組織 (WHO) 的數據，全球約 1% 的兒童患有癲癇症。其他因素，例如醫療保健成本上升、癲癇治療意識增強以及新抗癲癇藥物的推出，正在推動市場成長。但也存在市場抑制因素，如市場開拓成本高、兒童用用藥核准監管嚴格等。此外，抗癲癇藥物對兒童神經系統的副作用也成為一個問題。同時，疾病修正治療的研究和開發以及個人化抗癲癇藥物治療方案的發展對於未來的市場進入者來說是顯著的機會。
本研究的主要特點
- 本報告對全球小兒科抗癲癇藥物市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率（CAGR%）。
- 它還強調了各個細分市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
- 根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球小兒科抗癲癇藥物市場的主要參與者進行了分析。
- 本研究涵蓋的主要企業包括賽諾菲、Eisai、輝瑞、UCB SA、Sunovion Pharmaceuticals、雅培、Jazz Pharmaceuticals、Ovid Therapeutics Inc.、SK BIOPHARMACEUTICALS、Alexza Pharmaceuticals, Inc.、Taisho Pharmaceuticals. Holdings、Marinus Pharmaceticals Inc. .、 Xenon Pharmaceuticals Inc.、H. Lundbeck A/S、Teva Pharmaceutical Industries Ltd. 等。
- 該報告的見解將幫助行銷人員和經營團隊高層就未來的產品發布、升級、市場擴張和行銷策略負責人明智的決策。
- 全球小兒科抗癲癇藥市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 相關人員可以透過用於分析全球小兒科抗癲癇藥物市場的各種策略矩陣來促進他們的決策。
目錄
第1章 研究目的與前提
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、監理與趨勢分析
- 市場動態
- 促進因素
- 神經病變的發生率增加
- 增加研發活動
- 抑制因素
- 監管產品召回增加
- 抗癲癇藥物的副作用
- 市場機會
- 尚未開發的新興市場
- 標靶治療的需求不斷成長
- 影響分析
- 監管指引
- 產品發表會
- 主要進展
- PEST分析
- 波特的分析
- 監管場景
- 併購
- 製造商收益
- 按國家/地區分類的醫療保健支出
第4章全球小兒科抗癲癇藥物市場－新型冠狀病毒感染疾病（COVID-19）影響分析
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第5章2018-2030年全球小兒科抗癲癇藥物市場（依藥物類型）
- 第一代抗癲癇藥
- 第二代抗癲癇藥
- 第三代抗癲癇藥
第 6 章 全球小兒科抗癲癇藥物市場（依給藥途徑），2018-2030 年
- 口服
- 可注射的
- 其他（鼻子等）
第7章2018-2030年全球小兒科抗癲癇藥物市場（依分銷管道）
- 醫院藥房
- 零售藥房
- 網路藥房
第8章2018-2030年全球小兒科抗癲癇藥物市場（按地區）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第9章 競爭形勢
- Sanofi
- Eisai Co., Ltd.
- Pfizer Inc.
- Company Highlight
- UCB SA
- Company Highlight
- Sunovion Pharmaceuticals Inc.
- Abbott
- Jazz Pharmaceuticals plc
- Ovid Therapeutics Inc.
- SK BIOPHARMACEUTICALS
- Alexza Pharmaceuticals, Inc.
- Taisho Pharmaceutical Holdings Co., Ltd.
- Marinus Pharmaceuticals, Inc.
- Xenon Pharmaceuticals Inc.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
第10章
- 調查方法
- 關於出版商
簡介目錄
Product Code: CMI823
The global anti-epileptic drugs for pediatrics market size is expected to reach US$ 2,034.7 Mn by 2030, from US$ 1,202.4 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023/2024: | US$ 1,202.4 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: | 7.80% | 2030/2031 Value Projection: | US$ 2,034.7 Mn |
Figure 1. Global Anti-epileptic Drugs for Pediatrics Market Share (%), By Region, 2023
Epilepsy is a common neurological disorder that affects people of all ages globally. However, it is more prevalent in children as almost 70% of epilepsy cases are diagnosed before reaching adulthood. Anti-epileptic drugs play a crucial role in managing seizures and improving quality of life for pediatric patients suffering from epilepsy. These medications work by controlling abnormal neuronal firing and synchrony in the brain to prevent seizures. In recent years, extensive research has led to the development and approval of newer generation anti-epileptic drugs that are more effective and have less side effects than the earlier drugs for pediatric use. This has positively impacted medication adherence and treatment outcomes for children with epilepsy. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while a genetics related condition is called idiopathic epilepsy.
Market Dynamics
The global anti-epileptic drugs for pediatrics market is driven by the growing prevalence of epilepsy among children. According to the World Health Organization (WHO), epilepsy affects around 1% of children worldwide. Besides this, factors such as increasing healthcare expenditures, rising awareness about epilepsy treatment, and introduction of newer anti-epileptic drugs are fueling the market growth. However, the market faces certain restraints such as high costs associated with drug development and stringent regulations for the approval of pediatric drugs. Moreover, adverse effects of anti-epileptic drugs on developing neurological system of children poses challenges. On the positive side, ongoing research on disease modifying therapies and development of personalized anti-epileptic drug regimens present notable opportunities for market players in the future.
Key features of the study:
- This report provides an in-depth analysis of the global anti-epileptic drugs for pediatrics market, and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anti-epileptic drugs for pediatrics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as part of this study include Sanofi, Eisai Co., Ltd., Pfizer Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Abbott, Jazz Pharmaceuticals plc, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
- The global anti-epileptic drugs for pediatrics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs for pediatrics market
Detailed Segmentation:
- Global Anti-Epileptic Drugs for Pediatrics Market, Drug Type:
- First generation anti-epileptic drugs
- Second generation anti-epileptic drugs
- Third generation anti-epileptic drugs
- Global Anti-Epileptic Drugs for Pediatrics Market, Route of Administration:
- Oral
- Injectable
- Others (Nasal, etc.)
- Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anti-Epileptic Drugs for Pediatrics Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- Sanofi
- Eisai Co., Ltd.
- Pfizer Inc.
- UCB S.A.
- Sunovion Pharmaceuticals Inc.
- Abbott
- Jazz Pharmaceuticals plc
- Ovid Therapeutics Inc.
- SK BIOPHARMACEUTICALS
- Alexza Pharmaceuticals, Inc.
- Taisho Pharmaceutical Holdings Co., Ltd.
- Xenon Pharmaceuticals Inc.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trend Analysis
- Market Dynamics
- Drivers
- Increasing incidence of neurological disorders
- Increasing research and development activities
- Restraints
- Increasing product recalls by regulatory authorities
- Side effects of anti-epileptic drugs
- Market Opportunities
- Untapped emerging markets
- The rising demand for targeted therapy
- Impact Analysis
- Regulatory Guidelines
- Product Launches
- Key Development
- PEST Analysis
- PORTER's Analysis
- Regulatory Scenario
- Mergers and Acquisitions
- Manufacturer Revenue
- Healthcare Spending by Country
4. Global Anti-Epileptic Drugs for Pediatrics Market - COVID-19 Impact Analysis
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- First generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Second generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Third generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
6. Global Anti-Epileptic Drugs for Pediatrics Market, By Route of Administration, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Others (Nasal, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
7. Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Overview
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. Global Anti-Epileptic Drugs for Pediatrics Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- UCB S.A.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jazz Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ovid Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SK BIOPHARMACEUTICALS
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alexza Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Taisho Pharmaceutical Holdings Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Marinus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xenon Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
